Background: RNA interference (RNAi) provides an attractive tool to modulate biological systems, and ultimately, to treat human diseases. We describe early results from a Phase Ib, first-in-human safety and tolerability study of an RNAibased therapy, NUC B1000, among patients with mild to moderate chronic HBV. Methods: Three subjects received a single 5 mg DNA dose of NUC B1000 as part of a planned dose escalation study. Results: All participants reported pharyngitis, chills, myalgia and fever approximately 4-7 h after dosing. All subjects were asymptomatic after a single antipyretic dose with no symptom recurrences. Measurements of interferon (IFN)-α and -γ, interleukin (IL)-10, 12 18, 8 and 6, and tumour necrosis factor-α performed before and after dosing revealed cytokine increases before study drug administration. After drug administration, IFN-γ and IL-10 increased in two patients; IL-8 increased in one. Most increases returned to pretreatment levels within 1 week. Two patients were subsequently successfully treated with entecavir indicating that NUC B1000 does not compromise subsequent antiviral therapy. Conclusions: Thus far, NUC B1000 appears safe and well-tolerated; safety and efficacy studies across a larger, more diverse patient spectrum using increasing doses are needed to determine its appropriate role in the antiviral armamentarium.
Recent insights into the cellular basis for gene expression and regulation have provided scientists with attractive potential tools to modulate biological systems, and ultimately, to treat human diseases. Among these potential tools is RNA interference (RNAi). In this paper, we present early data from an ongoing study of safety and tolerability in a first-in-human evaluation of an expressed interfering RNA (eiRNA)-based therapy, NUC B1000, among patients with chronic HBV infection. The proprietary nature of these data imposes limitations; however, the authors felt the results merited presentation and discussion as they involve a first-in-human study with potentially important clinical implications.
Therapeutic potential of RNA interference
RNAi is an innate cellular mechanism whose discovery, mechanism of action and potential therapeutic applications have been eloquently described elsewhere [1] [2] [3] . Briefly, RNAi is a pathway which, when activated by a small double-stranded RNA (dsRNA), can lead to sequence-specific gene silencing [4] . When specific dsRNAs are expressed, sequence-homologous genes are silenced at the post-transcriptional level. Since the first description of post-transcriptional gene silencing in plants, and its subsequent descriptions in a range of animals, RNAi has been recognized as a powerful tool to modulate gene expression [5] [6] [7] [8] and is being evaluated by a number of groups as a new method to intervene in a variety of diseases.
As part of its development as a new therapeutic modality, broad applications of RNAi in therapeutic target identification and validation have been proposed, potentially greatly increasing the number of pharmacological targets for a wide range of diseases. Additionally, the growing knowledge of RNAi and its functions Introduction has fuelled the ongoing development of novel standalone RNAi-based therapeutics as well as combination products with vaccines, small molecule agonists and antagonists affecting protein function, and monoclonal antibodies against extracellular protein targets.
RNAi-based therapy has many theoretical advantages. It allows highly potent and specific gene silencing and can allow multiple targets on a single gene, or multiple targets on many genes to be addressed simultaneously. Such targeted activity, however, is predicated on the ability to deliver RNAi in a stable, non-toxic, biologicallyactive form to the target cell's interior. Furthermore, the use of RNAi can have unintended consequences that may result in serious side effects, such as systemic inflammatory response. Understanding and surmounting these challenges have subsumed much recent RNAi research.
NUC B1000: a novel RNAi-based treatment for chronic HBV An optimal treatment for HBV would simultaneously inhibit viral replication, down-regulate production of viral antigens that modulate and suppress much of the immune response that normally allows for viral clearance in humans, and prevent viral escape mutants that lead to drug resistance. Additionally, an ideal drug would remove viral proteins from the hepatocyte surface, thus obviating immune-mediated liver damage and cirrhosis. Finally, such ideal therapy would have activity against all genetic variants of HBV and be compatible with existing HBV therapies.
Nucleonics, Inc. (Horsham, PA, USA), a now defunct biotechnology company, developed an eiRNA-based HBV therapy, NUC B1000, which targets multiple sites on the HBV messenger RNA (mRNA). The active component of NUC B1000 is a proprietary eiRNA plasmid molecule encoding four distinct shRNAs mapping to different regions of the HBV genome. The first short hairpin RNA (shRNA) maps within the polymerase gene, whereas the other three shRNAs map throughout the hepatitis B surface antigen (HBsAg) genes. Expression of each shRNA is under the control of an RNA Pol III promoter. The plasmid is proprietary, precluding detailed discussion of its structure; however, Figure 1 depicts the general organization of the clinical plasmid and Figure 2 shows the target sites on the HBV mRNAs.
Exhaustive cell culture studies have demonstrated specific down-regulation of all HBV RNAs, including pregenomic RNA as compared with mismatch controls [9] (Nucleonics, Inc.; Alnylam Pharmaceuticals; CS and CP, unpublished data; Recombinant DNA Advisory Committee). Additionally, significant inhibition of HBV antigen expression and viral replication is also observed, and is consistent with mRNA knockdown (Nucleonics Inc. and Alnylam Pharmaceuticals; CS and CP, unpublished data). The product, NUC B1000, is composed of the RNAi plasmid complexed with cholesteryl spermine and assembled to form nanoparticles that are 80-150 nm in diameter.
NUC B1000 is intended for use as a multidose product, with each dose potentiating the hepatocyte uptake of subsequent doses. This is based on the The approximate target sites for each HBV short hairpin RNA (shRNA) on HBV messenger RNAs (mRNAs) are shown. Please note that HBV mRNAs are 3′ coterminal and have extensive overlapping sequences; therefore, three out of the four shRNAs actually target multiple HBV mRNA species. Pre-C, precore; Pre-S, pre-surface; S, surface; X, X-protein.
observed persistence of the plasmid component in liver for >100 days following administration of NUC B1000. When administered intravenously, the nanoparticle been shown in preclinical models to transfect hepatocytes and delivers the eiRNA plasmid to hepatocytes and to the cells of some other tissues ,such as the skin (Nucleonics, Inc. and Alnylam Pharmaceuticals, unpublished data).
In vivo proof-of-concept for HBV knockdown was demonstrated in a transient HBV transgenic mouse model. The transient HBV model used in this experiment is one in which mouse hepatocytes transiently express all of the HBV surface antigens (L, M and small). The different forms of surface antigens are all secreted from the hepatocytes and can be detected in blood at levels similar to those observed in chronically infected patients. The mouse model was created by hydrodynamic injection of an HBV expression plasmid into the tail vein. Mice utilized were NOD/ scid and expression of all surface antigens persists for ≥1 month. NUC B1000 is the formulated drug product and contains the API plasmid. NUC B1000 was dosed intravenously into the tail vein of mice using a bolus dose of 200 µl. It was not administered via the hydrodynamic method.
In this model, only NUC B1000 showed anti-HBV activity; the formulation-matched control, comprising an eiRNA plasmid expressing mismatched hairpins complexed with cholesteryl spermine did not. Therefore, down-regulation through a non-specific, immunomodulation pathway effected by the nanoparticle is unlikely [9] (CS and CP, unpublished data).
Preliminary data showed that 1% of mouse hepatocytes were transfected. Subsequent experiments in which spike recovery was performed demonstrated that nearly 10% of cells were transfected; actual rates varied between 6% and 9% (Nucleonics, Inc. and Alnylam, unpublished data). A number of explanations for the discrepancy between this rate and the 20% knockdown of HBsAg have been postulated. These include an actual transfection rate that was slightly higher than what was measured in the QRT-PCR assay, variation observed between experiments in which biodistribution and HBsAg were measured or spreading of shRNA from transfected hepatocytes to other hepatocytes, resulting in a situation in which the number of hepatocytes that have taken up the eiRNA plasmid is less than the number of cells containing the encoded shRNA [10, 11] . Such cell-spreading phenomenon is known to occur in plants and invertebrates [10] . Subsequent data published by another group demonstrates that the SID-1 receptor, the receptor responsible for cell-to-cell spread, mediates uptake of small interfering RNA (siRNA) in mice following systemic administration of a formulated siRNA. This is the first published data showing activity of this receptor in mice and it is therefore tempting to speculate that this receptor may also be responsible for trafficking of si/shRNA from one cell to an adjacent cell, which is the case in plants and invertebrates. Therefore, it is predicted that NUC B1000 will effectively transfect hepatocytes and possibly other cells in humans, a property that will help minimize viral escape. NUC B1000 does not enter brain or gonadal tissue (Nucleonics, Inc. and Alnylam, unpublished data).
It is hypothesized that efficacy in humans will not require transfection of 100% of hepatocytes but merely sufficient reduction of HBsAg to overcome immune anergy and immune exhaustion, thus allowing the induction of an anti-hepatitis B e antigen (HBeAg), -hepatitis B core antigen (HBcAg) and -HBsAg immune response. In addition to the direct benefits of HBV suppression, reduction in antigenaemia is predicted to diminish immune-mediated liver damage.
Preclinical in vitro and in vivo studies in mice and dogs of NUC B1000 suggest a good safety profile, demonstrating no induction of stress responses (proinflammatory cytokines or type I or type II interferons), no sequence-dependent or independent off-target effects, and no competition or saturation of endogenous RNAi [9] (Nucleonics, Inc. and Alnylam, unpublished data). Murine toxicology studies using dosages 15× greater than dosages given to humans, and studies in dogs using both high dosages and infusion rates 3× those given to humans showed good tolerability [9] .
Methods
This Phase Ib clinical evaluation of the safety of NUC B1000 in humans was designed to include five cohorts each of three patients to be observed periodically over a 1 year period. As is typical of a Phase I study, this study emphasized qualitative assessments safety and tolerability. No meaningful statistical analysis could be performed nor was one planned as the study was expected to enrol low numbers in each phase. The study included HBV-infected people with mild-to-moderate liver disease characterized by fibrosis of stage 3 or less (modified Knodell score), and enrolled participants from United States and Serbia. The FDA precluded the use of a placebo arm for this study.
The first cohort was enrolled and treated; however, observation for the entire planned duration and completion of the study with subsequent cohorts was suspended when the sponsoring company entered financial reorganization. Specific inclusion criteria allowed participation of men and women aged 21-65 years with chronic HBV infection (HBsAg-positive) for ≥6 months duration, whose HBV titre exceeded 10 5 , and whose ALT levels were at or above 2× the upper limit of normal as defined by the American Association for the Study of Liver Disease 2007 guidelines [12] . Additionally, participants needed documentation that they had mild to moderate chronic active HBV, and had to be able to provide written informed consent indicating awareness of the investigational nature of this study.
Exclusion criteria consisted of evidence of an intercurrent medical disorder, such as HIV infection or AIDS, active or chronic hepatitis C or hepatitis delta viral infection, autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, anti-DNA or anti-chromatin antibodies and other autoimmune diseases), congestive heart failure or clinically significant cardiac disease, asthma, chronic obstructive pulmonary disease, diabetes mellitus, splenomegaly, portal hypertension, ascites, liver fibrosis or cirrhosis, history of anaphylaxis, unexplained abnormal erythrocyte sedimentation rate or c-reactive protein, abnormal albumin, creatinine, or white cell count, proteinuria, or thrombocytopenia (platelets <10 5 ), and decompensated liver disease. In addition, those taking medications such as immunomodulatory, antiviral, investigational drugs or certain supplements were excluded as were those who were pregnant or nursing, those unable to provide written informed consent, and those unable to return for scheduled treatments and assessments. Full inclusion and exclusion details can be found in Additional file 1.
Cytokine assays were performed by ACM Medical Labs (Rochester, NY, USA) through Pharm-Olam International (Houston, TX, USA), a multinational contract research organization. Cytokine analyses were performed using a Linco multiplexed fluorescent microsphere kit (Millipore Inc., Billerica, MA, USA). Samples were compared to known positive and negative controls to ensure that responses correlated appropriately and to assess the relative significance of changes in the cytokine profile using ELISA-based colorimetric assays.
The lower limits of quantification for cytokines were: interferon (IFN)-α 13 ng/l, IFN-γ 2 ng/l, IL-10 2 ng/l, IL-12 12 ng/l, IL-18 13 ng/l, IL-8 8 ng/l, IL-6 2 ng/l, and tumour necrosis factor (TNF)-α 5ng/l. PCR-based assays for HBV DNA (Roche TaqMan Realtime PCR; qualitative test sensitivity of 15 IU/ml, quantification limit of 200 IU/ml; Roche Molecular Diagnostics, Pleasanton, CA USA.
Primary endpoints included the following safety measures: liver enzymes, liver function, CRP, ESR, rheumatoid factor, cytokine measures and vital signs. Side effects were classified using established guidelines [13] . Secondary endpoints were efficacy measures including viral titres and antigen levels. Participants were admitted to an inpatient clinical study unit where they were monitored during and after intravenous infusion of NUC B1000.
This study was approved by the Institutional Review Board of California Pacific Medical Center, the National Institutes of Health Recombinant DNA Advisory Committee, and by the institutional review board of the Clinical Centre of Serbia.
Results
In the initial cohort, three male participants between the ages of 35 and 55 years who met all inclusion and exclusion criteria received the study drug; baseline demographics are shown in Table 1 . All study participants experienced similar symptoms, which were classified as mild using established criteria and which did not require significant treatment or study withdrawal. Initial reactions included symptoms for patient US1-101 of pharyngitis, chills and myalgia, which began approximately 4-5 h after dosing, and fever occurring approximately 6 h after dosing (maximum 39.2°C, lasting approximately 4 h). Patient US1-102 experienced chills and nasal congestion also occurring approximately 4 h after dosing, and fever occurring approximately 7 h after dosing (maximum 39.2°C, lasting approximately 4 h). Patient SE1-103, had symptoms of throat irritation, chills and nausea also beginning about 4 h after dosing accompanied by fever approximately 5 h after dosing (maximum 38.5°C, duration approximately 5 h). All participants were asymptomatic within 2-3 hours of treatment with a single antipyretic dose; no recurrences occurred.
Evaluations of cytokines including IFN-α and -γ, interleukin (IL)-10, -12, -18, -8 and -6, and TNF-α were performed before and after dosing ( Table 2) . As expected, participants had evidence of increased cytokines before receiving the study drug. Posttreatment, patient US1-101 experienced a new increase of IFN-γ, IL-10 and a significant increase of IL-18, patient US1-102 experienced a measurable increase of IL-18, and patient SE1-103 experienced increases of IFN-γ, IL-10, IL-18 and IL-8. Notably, the majority of measurements taken 1 week after dosing had returned to pretreatment levels. The antiviral effects of NUC B1000 were varied (Table 3 ). In patient US1-101, HBV DNA increased to a level slightly greater than baseline by 6 weeks posttreatment. HBeAg and HBsAg remained below baseline 6 weeks post-treatment. Patient US1-102 also had virological parameters that remained below baseline 6 weeks post-treatment. At 6 weeks post-treatment, patient SE1-103 experienced HBV DNA and HBsAg levels that were slightly higher than observed at baseline. Two patients were subsequently treated with entacavir with profound suppression of HBV DNA.
Discussion

RNA interference: therapeutic challenges
The theoretical advantages of RNAi-based therapeutics must be balanced against potential side-effects. RNAi may induce both sequence-dependent and sequenceindependent off-target effects. Sequence-dependent effects result when the specific siRNA has significant partial complementarity to a non-target endogenous mRNA. Sequence-independent effects include more generalized activation of cellular stress responses. In mammals, dsRNA-mediated stress responses result in the induction of proinflammatory responses.
The eiRNA used in this study was designed to circumvent these off-target events and avoid the dsRNA-induced systemic inflammatory response seen with the direct application of RNA intravascularly. Synthetic RNAi can induce innate immune responses via TLRs and cause acute systemic toxicity including cardiac toxicity, infusion reactions and localized perivascular inflammation at the injection site. Expressed shRNA appears to avoid these responses probably because expressed shRNA does not interact with endosome interiors. Furthermore, some but not all stress responses are mediated through tolllike receptor (TLR) effects. Because extensive in vitro data demonstrated the lack of TLR activation and other stress responses, and because others have demonstrated the inability of expressed shRNA to access TLR receptors, we believe that the inflammatory response seen in these patients was most likely induced by the particle and unlikely to be a result of direct TLR stimulation. Data from human studies indicates that there is no endosome capture of shRNA [14] . In addition to off-target effects, RNAi can potentially saturate the cell's endogenous RNAi machinery, again leading to more generalized cell dysfunction. Our in vivo and in vitro studies showed that saturation of the eiRNA or miRNA pathway did not occur. In our confirmed in vitro data, doses 3,000-fold greater than the 50% effective dose (ED 50 ) were required to achieve saturation (CS and CP, data not shown).
Evidence from one animal study published by another group indicates that the use of shRNA that are highly expressed from viral vectors may oversaturate endogenous miRNA pathways. In this study evaluating RNAi-based anti-HBV in mice, shRNA-related micro-RNA oversaturation resulted in high rodent fatality rates [6] . However, it should be noted that this toxicity occurred using doses that greatly exceeded the predicted efficacious dose in humans and the study should be considered as a maximum tolerated dose for this particular viral vector and not necessarily applicable to plasmid-based technologies.
Delivery of active, non-toxic RNAi to target cells can also lead to unintended consequences. Vector delivery, as has been used previously in gene therapies, has been implicated in serious adverse events related to both immune responses to the foreign proteins and to integration of these proteins into the patient's DNA. DNA integration is also a potential concern for RNAi approaches that use non-viral, plasmid-based vectors. DNA integration frequency is dependent on two primary factors: DNA replication and plasmid copy number in the nucleus. Thus, RNAi therapies using plasmid-based vectors that do not replicate are much less likely to cause DNA integration, especially when targeted to slowly dividing tissues such as hepatocytes. While potential integration of foreign DNA into human hepatocytes raises concerns, few relevant data exist to help characterize the likelihood of, or factors associated with, such an event. Evaluation of data from patients with chronic HBV show that covalently closed circular DNA (cccDNA) does integrate periodically into host chromosomes. Furthermore, it has been estimated that it takes decades for such an integration event to occur in an infected human [10] . In infected patients, cccDNA is present at approximately 30-50 copies per infected cell and nearly all hepatocytes are infected. This number of DNA copies is several orders of magnitude higher than the number of DNA copies found in liver tissue following a single dose of NUC B1000. Additionally, hepatocytes divide very slowly: it is estimated that hepatocytes turn over, on average, approximately once every 3-5 years. Although this rate increases in those with chronic hepatitis, particularly among those with the most active disease, the maximal predicted turnover rate is about once in 7-18 months. Thus, based on the hepatocyte turnover rate, the low copy number of episomal DNA per hepatocyte, the low frequency of plasmid integration in mouse models, the non-random nature of the HBV genomic sequence that integrates and the length of time it takes for integration to occur, DNA integration after NUC B1000 administration is considered a remote possibility unlikely to occur at a rate greater than the natural mutation rate.
Our results also suggest the activity of a TLR effect. Specifically, IL-10 production is typically reduced in the liver in chronic HBV [14] ; the current observation of increased circulating IL-10 may be due to activation of a TH-2 response resulting from depression of the immune response against HBV. TLR may mediate this response. TLR-3, -7, -8 and -9 are found in the endosome and arise from signalling pathways that facilitate entry into the nucleus in the presence of increased IL-18 and INF-γ [14, [15] [16] [17] .
Finally, HBV DNA and HBsAg did not decrease in this study. A dose escalation study may be necessary to demonstrate this effect; however, we do not anticipate proportional increase in potential cytokine effects. If patients require higher NUC B1000 dosages, there would be no change in the delivery vehicle volume and only very small changes in RNAi molecule that would not be expected to substantially change the cytokine profile.
Conclusions
The early results of this descriptive, first-in-man safety study of an RNAi therapy conducted among patients with HBV demonstrate a reasonable safety profile. Further evaluations to expand safety and compile efficacy data, including study of a placebo or inactive eiRNA-based plasmid model are needed before this technology can undergo full Phase II or III trials. Studies conducted among larger, more diverse groups of patients are also necessary to acquire a clearer picture of both the therapeutic potential and risks of NUC B1000 specifically, and of the emerging class of RNAibased therapies in general.
Ultimately, if new technology such as RNAi can effectively and durably halt viral protein production, it may result in much higher rates of HBsAg loss and conversion to seronegative status. In turn, this may allow patients to discontinue therapy, currently an elusive goal for most patients taking oral antiviral medications.
